Neuroblastoma (NB) is a common and aggressive tumor of early childhood. To date, treatment with chemotherapy, surgery, and radiation therapy has resulted in suboptimal outcomes in those with advanced disease. Immune-based treatments hold promise for patients with recurrent or advanced NB. Here, recent preclinical studies and early stage (phase I) clinical trials using cellular therapeutic approaches for NB are reviewed, including studies of natural killer cells, gammadelta T cells, chimeric receptor expressing T cells, dendritic cells, and allogeneic hematopoietic cell transplant.
Recent developments in cell-based immune therapy for neuroblastoma. Publishing Authors By Initials
Recent developments in cell-based immune therapy for neuroblastoma. Journal Published:
PUBLICATION TYPE: Research Support, Non-U.S. Gov
Journal: Journal of neuroimmune pharmacology : the official
VOLUME: 2
Page Numbers: 134-9
Journal Abbreviation:
ISSN: 1557-1904
DAY: 2
MONTH: 03
YEAR: 2007
Recent developments in cell-based immune therapy for neuroblastoma. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 101256586
Recent developments in cell-based immune therapy for neuroblastoma. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Recent developments in cell-based immune therapy for neuroblastoma. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Recent developments in cell-based immune therapy for neuroblastoma.
AFFILIATION: Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Mayo Mail Code 366, 420 Delaware Street, S.E., Minneapolis, MN 55455, USA. verneris@umn.edu
Country: United States
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: J Neuroimmune Pharmacol
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Recent developments in cell-based immune therapy for neuroblastoma Related Publications